GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shandong Weigao Group Medical Polymer Co 1066.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

3.36

-1.47%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥15.59bn

FY2016FY2025

Net income

CN¥1.88bn

FY2016FY2025

Free cash flow

CN¥2.00bn

FY2016FY2025

Shareholders' equity

CN¥28.09bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥15.59bnCN¥13.09bnCN¥15.41bnCN¥15.86bnCN¥15.32bnCN¥13.53bnCN¥12.07bnCN¥10.26bnCN¥7.33bnCN¥7.84bn
Gross profitCN¥7.37bnCN¥6.58bnCN¥7.74bnCN¥8.51bnCN¥8.56bnCN¥7.52bnCN¥7.58bnCN¥6.28bnCN¥4.65bnCN¥4.82bn
Research and developmentCN¥924.6mCN¥625.2mCN¥851.7mCN¥636.5mCN¥573.1mCN¥479.1mCN¥473.2mCN¥362.4mCN¥318.9mCN¥352.5m
Operating incomeCN¥2.06bnCN¥2.27bnCN¥2.42bnCN¥3.42bnCN¥3.36bnCN¥2.73bnCN¥3.15bnCN¥2.38bnCN¥1.82bnCN¥1.61bn
Net incomeCN¥1.88bnCN¥2.07bnCN¥2.33bnCN¥3.22bnCN¥2.65bnCN¥2.43bnCN¥2.15bnCN¥1.72bnCN¥1.52bnCN¥1.29bn
Diluted earnings per share0.410.450.510.710.580.540.480.380.340.29

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥42.00bnCN¥40.48bnCN¥39.21bnCN¥38.66bnCN¥35.36bnCN¥31.84bnCN¥30.66bnCN¥27.93bnCN¥19.54bnCN¥18.35bn
Cash and short-term investmentsCN¥11.49bnCN¥9.69bnCN¥8.54bnCN¥8.72bnCN¥8.31bnCN¥6.97bnCN¥5.43bnCN¥4.85bnCN¥4.41bnCN¥4.74bn
Total liabilitiesCN¥11.92bnCN¥10.97bnCN¥11.27bnCN¥11.35bnCN¥11.02bnCN¥10.43bnCN¥10.86bnCN¥10.24bnCN¥3.66bnCN¥4.14bn
DebtCN¥5.94bnCN¥4.19bnCN¥4.17bnCN¥4.49bnCN¥4.14bnCN¥4.32bnCN¥5.52bnCN¥5.34bnCN¥1.01bnCN¥1.19bn
Shareholders' equityCN¥28.09bnCN¥27.66bnCN¥26.14bnCN¥25.23bnCN¥22.44bnCN¥20.43bnCN¥18.85bnCN¥16.90bnCN¥15.53bnCN¥13.82bn
Shares outstanding4,534m4,569m4,530m4,552m4,534m4,522m4,522m4,491m4,483m4,433m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥2.97bnCN¥2.79bnCN¥3.26bnCN¥2.58bnCN¥3.53bnCN¥3.14bnCN¥2.70bnCN¥2.58bnCN¥1.68bnCN¥1.23bn
Capital spending−CN¥969.6m−CN¥596.7m−CN¥798.5m−CN¥1.30bn−CN¥1.30bn−CN¥1.16bn−CN¥1.15bn−CN¥926.3m−CN¥1.92bn−CN¥744.2m
Free cash flowCN¥2.00bnCN¥2.19bnCN¥2.46bnCN¥1.28bnCN¥2.23bnCN¥1.98bnCN¥1.56bnCN¥1.66bn−CN¥237.2mCN¥482.1m
Dividends paid−CN¥1.20bn−CN¥870.6m−CN¥853.2m−CN¥863.6m−CN¥760.8m−CN¥816.7m−CN¥828.5m−CN¥253.8m−CN¥658.7m−CN¥294.1m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
RevenueCN¥7.87bnCN¥7.85bnCN¥7.74bnCN¥6.45bnCN¥3.76bnCN¥6.64bnCN¥3.86bnCN¥6.33bn
Gross profitCN¥3.64bnCN¥3.52bnCN¥3.85bnCN¥3.16bnCN¥1.84bnCN¥3.38bnCN¥1.97bnCN¥3.07bn
Operating incomeCN¥1.30bnCN¥609.2mCN¥1.37bnCN¥1.01bnCN¥588.0mCN¥1.26bnCN¥735.4mCN¥664.4m
Net incomeCN¥889.0mCN¥703.2mCN¥1.17bnCN¥959.1mCN¥558.5mCN¥1.11bnCN¥644.9mCN¥804.1m
Diluted earnings per share0.200.160.260.210.120.240.140.18
Cash from operations—CN¥2.01bnCN¥1.03bnCN¥1.77bn—CN¥1.02bnCN¥595.0mCN¥1.96bn
Capital spending—−CN¥2.01bn—−CN¥598.0m———−CN¥754.0m
Free cash flow—CN¥0—CN¥1.17bn———CN¥1.20bn
Total assetsCN¥41.41bnCN¥42.00bnCN¥42.09bnCN¥34.76bnCN¥40.48bnCN¥34.54bnCN¥40.23bnCN¥39.21bn
Cash and short-term investmentsCN¥10.39bnCN¥11.49bnCN¥11.24bnCN¥8.32bnCN¥9.69bnCN¥7.87bnCN¥9.16bnCN¥8.54bn
DebtCN¥2.55bnCN¥5.94bnCN¥6.42bnCN¥4.19bnCN¥1.45bnCN¥4.13bnCN¥784.7mCN¥4.86bn
Shareholders' equityCN¥28.40bnCN¥28.09bnCN¥28.07bnCN¥23.75bnCN¥27.66bnCN¥23.08bnCN¥26.87bnCN¥26.14bn

Financial ratios

Data as of 28 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin47.3%50.3%50.2%53.6%55.9%55.6%
Operating margin13.2%17.4%15.7%21.6%22.0%20.2%
Net margin12.0%15.8%15.1%20.3%17.3%18.0%
Return on equity6.7%8.7%8.9%12.8%11.8%11.9%
Return on assets4.5%5.9%5.9%8.3%7.5%7.6%
Free cash flow yield22.9%22.8%23.6%22.5%28.1%25.1%
Revenue growth2.3%-1.1%-2.9%3.6%13.2%12.1%
Earnings growth-22.0%3.2%-27.6%21.4%9.1%13.1%
Current ratio3.78x3.20x2.46x3.08x3.14x3.14x
Debt to equity0.20x0.17x0.18x0.20x0.21x0.24x
Equity ratio66.9%68.3%66.7%65.3%63.4%64.2%
Interest coverage7.09x9.11x7.62x15.34x20.57x13.11x
R&D as a share of sales5.9%4.8%5.5%4.0%3.7%3.5%
Buybacks as a share of market value0.8%-0.9%0.5%-0.4%-0.3%0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.6%2.9%8.5%
Operating income-15.6%-5.5%2.8%
Net income-16.4%-5.0%3.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin48.6%50.4%52.1%55.3%
Operating margin15.1%17.0%18.3%20.1%
Net margin13.8%15.8%16.4%16.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings10.58.812.815.714.428.211.814.716.615.4
Price to sales1.31.41.93.22.55.12.12.53.42.5

Dividends and splits

Per share, in the currency the company pays

Paid for 22 years. Last went ex-dividend on 2 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.0690.3370.2240.2460.1720.1750.1390.125
  • 2-for-1 split · 4 May 2011
  • 2-for-1 split · 7 Sept 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.